Inhibiting cyclin D1–CDK6 suppresses senescence-associated inflammatory gene expression and age-related functional decline

Adarsh Rajesh, Aaron P. Havas, Peter D. Adams

1. 01

   Cyclin D1 and CDK6 regulate SASP inflammatory gene expression in senescent cells

2. 02

   Mechanism runs through DNA damage and cGAS–STING pathway activation

3. 03

   Palbociclib improved motor function and reduced frailty measures in aged mice

4. 04

   Positions CDK4/6 inhibition as a senomorphic strategy that does not require killing senescent cells

5. 05

   Published alongside a companion Nature Aging paper (Wang et al., abemaciclib) with a joint News & Views on CDK4/6 repurposing

Study Design

Preclinical Study

Sample Size

Not reported

Study Duration

Not specified (aged mouse cohorts)

Methodology

Genetic and pharmacological manipulation of cyclin D1 and CDK6 in senescent cell models and in aged mice; transcriptomic profiling of SASP inflammatory gene expression; mechanistic dissection of DNA damage and cGAS–STING involvement; in vivo palbociclib dosing with motor function and frailty index endpoints in aged mice.

Limitations

Entirely preclinical — mouse and cell-based, with no aging-indication human data. Endpoints are functional (motor performance, frailty) rather than survival. Palbociclib is a myelosuppressive oncology agent with established neutropenia, fatigue, infection and interstitial lung disease risks; the mouse dosing schedule has no validated human geroprotective equivalent. Provides no basis for off-label use.